Zometa

Osteoporosis, Chemotherapy, Osteoporosis + 10 more

Treatment

20 Active Studies for Zometa

What is Zometa

Zoledronic acid

The Generic name of this drug

Treatment Summary

Zoledronic acid (also known as CGP 42'446) is a medication used to treat and prevent a variety of bone-related conditions, including osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. It was first approved by the FDA in 2001 and is classified as a third-generation, nitrogen-containing bisphosphonate, similar to ibandronic acid, minodronic acid, and risedronic acid.

Zometa

is the brand name

image of different drug pills on a surface

Zometa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zometa

Zoledronic acid

2001

53

Effectiveness

How Zometa Affects Patients

Zoledronic acid is a medication used to prevent bone loss that works by blocking the action of osteoclasts. It has a wide range of therapeutic benefits and does not typically cause severe side effects from an overdose. However, it can cause issues such as electrolyte deficiencies, renal impairment, jaw necrosis, fractures, lung constriction, liver damage, low calcium levels, and harm to unborn babies. Patients should be aware of these risks before taking the medication.

How Zometa works in the body

Bisphosphonates work in the body by attaching to bone, which prevents the osteoclasts from breaking down the bone and causes them to detach. This stops the bone from being broken down and resorbed. In addition, nitrogen-containing bisphosphonates like zoledronate also block the mevalonate pathway, which is necessary for certain proteins to function and survive. This causes them to die off, which helps to stop the spread of tumor cells. Finally, zoledronate activates caspases, which also contributes to cell death.

When to interrupt dosage

The proposed amount of Zometa is contingent upon the diagnosed ailment, including Bone Mineral Density, Paget’s Disease and Osteoporosis caused by glucocorticoid. The amount of dosage is subject to the administration procedure featured in the table below.

Condition

Dosage

Administration

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Bone Metastases

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Malignant Neoplasms

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Paget’s Disease

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Chemotherapy

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Multiple Myeloma

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Glucocorticoids

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Disease

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Postmenopause

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteitis Deformans

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Zometa Contraindications

Condition

Risk Level

Notes

Renal Insufficiency, Chronic

Do Not Combine

Hypocalcemia

Do Not Combine

Acute Kidney Injury

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Zoledronic Acid may interact with Pulse Frequency

There are 10 known major drug interactions with Zometa.

Common Zometa Drug Interactions

Drug Name

Risk Level

Description

Alendronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.

Clodronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.

Etidronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.

Ibandronate

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.

Incadronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Incadronic acid.

Zometa Toxicity & Overdose Risk

Overdosing on a drug may cause reduced kidney function, low levels of calcium, phosphorus, and magnesium in the blood. If this occurs, intravenous treatment with the lacking ions is necessary.

image of a doctor in a lab doing drug, clinical research

Zometa Novel Uses: Which Conditions Have a Clinical Trial Featuring Zometa?

320 active clinical trials are assessing the efficacy of Zometa in providing relief for Osteoporosis, Malignant Neoplasms and Solid Tumors.

Condition

Clinical Trials

Trial Phases

Osteoporosis

3 Actively Recruiting

Not Applicable, Phase 2

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Bone Metastases

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 3

Disease

1 Actively Recruiting

Not Applicable

Osteoporosis

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

Glucocorticoids

0 Actively Recruiting

Paget’s Disease

0 Actively Recruiting

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Osteoporosis

0 Actively Recruiting

Osteitis Deformans

0 Actively Recruiting

Zometa Reviews: What are patients saying about Zometa?

5

Patient Review

10/12/2016

Zometa for Lesions in the Bone of the Disease Multiple Myeloma

I've had this treatment three times now and have yet to experience any negative side-effects. The process is spread out over 30 minutes, which I appreciate.

5

Patient Review

6/24/2014

Zometa for Cancer that has Spread To the Bone From Solid Tumors

I've been getting monthly IV infusions of Zometa for 18 months now, and I haven't had any noticeable side effects other than a bit of fatigue when I first started taking it (but that might have also been because I was starting other medications at the same time). It's definitely helped with my pain levels too - I'm still able to exercise 4 km. every day on the treadmill! All in all, I'm really happy with this medication.

5

Patient Review

1/11/2018

Zometa for Lesions in the Bone of the Disease Multiple Myeloma

Before treatment, I could barely walk due to the compression fractures in my spine. A year later and I'm in remission thanks to incredibly effective drugs and therapies. Nowadays, you would never know that I ever had a problem if I didn't tell you.

4.3

Patient Review

8/29/2020

Zometa for Osteoporosis caused by Anti-Androgen Drugs

I've been on this medication for six months now, and I have to say that it's helped me a lot. I was worried about bone loss due to the anti-hormone drug I take, but this has really reduced my risk. I still get some joint pain and fatigue, but it's nothing compared to what it used to be.

4

Patient Review

5/18/2022

Zometa for prevention of skeletal related events in multiple myeloma

I had some pain after my first infusion, which was to be expected. What I didn't expect was how long it would last! Make sure to take Tylenol before and after your treatment.

3.7

Patient Review

7/13/2014

Zometa for Osteoporosis

I experienced quite a bit of bone pain after my last infusion.

2.3

Patient Review

2/7/2017

Zometa for Lesions in the Bone of the Disease Multiple Myeloma

I unfortunately experienced some pretty intense side effects from this medication. It literally eroded my lower jaw on the right side due to the acidity. Has anyone else had a similar experience?

2.3

Patient Review

4/25/2015

Zometa for Increased Calcium in the Blood from Cancer

Each monthly treatment results in me feeling flu-like and exhausted for five to seven days.

1.3

Patient Review

7/1/2022

Zometa for Osteoporosis

I had a Zometa infusion for osteoporosis because of taking Exemestane (estrogen blocker). I had it done by 3:30 pm yesterday and by the early morning I was in excruciating pain in bone and joints! I almost passed out and felt nauseous. I’m still in pain but I will never take that again!!!

1

Patient Review

10/2/2020

Zometa for Cancer that has Spread To the Bone From Solid Tumors

After just a single infusion, I'm now struggling with basic movements and my fatigue is debilitating. My body hurts all over, and I won't be getting another infusion.

1

Patient Review

8/26/2022

Zometa for Osteoporosis

Zometa was honestly the worst drug I've ever taken. I experienced severe pain in my bones, muscles, and joints for four months straight.

1

Patient Review

1/29/2019

Zometa for Increased Calcium in the Blood from Cancer

I was extremely sick after receiving this medication intravenously at the doctor's office. I had no idea what it was or why he ordered it, and it made me incredibly ill for over a week. I would never knowingly choose to receive this drug again.

1

Patient Review

3/10/2019

Zometa for Cancer that has Spread To the Bone From Solid Tumors

I had an absolutely miserable experience with this drug. I developed a headache and intense body pain within hours of taking it, and neither subsided for almost two full days. On top of that, my acid reflux flared up badly and I coughed constantly. Would not recommend at all.

1

Patient Review

10/30/2019

Zometa for Glucocorticoid-Induced Osteoporosis Prevention

Unfortunately, I now have jaw necrosis as a result of using this treatment.

1

Patient Review

6/2/2014

Zometa for Cancer that has Spread To the Bone From Solid Tumors

I strongly disliked this medication. I had two rounds of it and both times experienced flu-like symptoms for four days straight. On top of that, I've now lost all feeling in my fingers and have constant pain in my arms. This makes everyday tasks incredibly difficult.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zometa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Zometa chemotherapy?

"Zoledronic acid is not a cancer chemotherapy, however it can be used to treat bone disease in patients who have cancer. Zoledronic acid is in a class of medications called bisphosphonates."

Answered by AI

What does Zometa do to your body?

"This medication works by reducing the amount of calcium that is released from the bones into the bloodstream. It also slows down the rate at which cancer cells break down bones, which helps to prevent fractures."

Answered by AI

What are the long term side effects of Zometa?

"Some possible symptoms of a brain tumor could include changes in vision, decreased frequency of urination, increased tearing, heavy feeling in the jaw, and increased blood pressure."

Answered by AI

Is Zometa cancer treatment?

"The drug Zometa is approved by the FDA to treat multiple myeloma and bone metastases from solid tumors. It is typically used in conjunction with other standard treatments for cancer, such as chemotherapy, radiation therapy, and hormone therapy. Zometa is also sometimes used to treat bone metastases specifically from prostate cancer."

Answered by AI

Clinical Trials for Zometa

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Waitlist Available
Has No Placebo

UPMC Hillman Cancer Center

Carissa A Low

Have you considered Zometa clinical trials?

We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Go to Trials
Image of University of Virginia Medical Center in Charlottesville, United States.

Estrogen for Bone Health in Amenorrhea

14 - 25
Female
Charlottesville, VA

The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control. Participants will: Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin) Take provided calcium and vitamin D supplements Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include: History and Physical Exams Lab Work Imaging studies Questionnaires Dietary recalls

Phase 2
Recruiting

University of Virginia Medical Center (+1 Sites)

Madhusmita Misra, MD, MPH

Image of Rutgers University - NJ Inst Food Nutrition & Health in New Brunswick, United States.

Peanut Snacks for Weight Loss

50 - 75
All Sexes
New Brunswick, NJ

The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.

Recruiting
Has No Placebo

Rutgers University - NJ Inst Food Nutrition & Health

Have you considered Zometa clinical trials?

We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD

Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.

Waitlist Available
Has No Placebo

University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)

Denise Orwig, PhD

Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada

Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.

Waitlist Available
Has No Placebo

Arthritis Research Canada (+5 Sites)

Lora Giangregorio, PhD

Have you considered Zometa clinical trials?

We made a collection of clinical trials featuring Zometa, we think they might fit your search criteria.
Go to Trials